Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors
about
Management of the patient with incomplete response to PPI therapy.Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.Modern medical and surgical management of difficult-to-treat GORD.Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoringACG practice guidelines: esophageal reflux testing.Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study.Effect of omeprazole on symptoms and ultrastructural esophageal damage in acid bile reflux.Effects of (2R)-(3-amino-2-fluoropropyl)sulphinic acid (AFPSiA) on transient lower oesophageal sphincter relaxation in dogs and mechanism of hypothermic effects in mice.Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease.Does Cholecystectomy Increase the Esophageal Alkaline Reflux? Evaluation by Impedance-pH Technique.Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next?Review: what do we mean by GERD?--definition and diagnosis.Pharmacological targets in gastro-oesophageal reflux disease.An update on the available treatments for non-erosive reflux disease.Review article: modern technology in the diagnosis of gastro-oesophageal reflux disease--Bilitec, intraluminal impedance and Bravo capsule pH monitoring.Current and emerging therapies for the management of functional gastrointestinal disorders.The role of GABA(A) receptors in the control of transient lower oesophageal sphincter relaxations in the dogRefractory heartburn to proton pump inhibitors: epidemiology, etiology and management.The Proton Pump Inhibitor Non-Responder: A Clinical ConundrumAmbulatory reflux monitoring in GERD--which test should be performed and should therapy be stopped?Pathogenesis of gastro-oesophageal reflux disease and novel options for its therapy.Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humansA proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease.Multichannel intraluminal impedance and pH monitoring in gastroesophageal reflux disease.Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group.Emerging drugs for gastroesophageal reflux disease.Review article: the clinical relevance of transient lower oesophageal sphincter relaxations in gastro-oesophageal reflux disease.Barrett's esophagus: proton pump inhibitors and chemoprevention I.Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation.Therapeutic options for refractory gastroesophageal reflux disease.Evolving pharmacological approaches in gastroesophageal reflux disease.Novel therapeutics for gastro-esophageal reflux symptoms.Refractory gastroesophageal reflux disease.Current pharmacological management of gastroesophageal reflux disease.Endotherapy for and tailored approaches to treating GERD, and refractory GERD.The role of bile acids in functional GI disorders.The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trialsReview of antireflux procedures for proton pump inhibitor nonresponsive gastroesophageal reflux disease.The relevance of transient lower oesophageal sphincter relaxations in the pathophysiology and treatment of GORD.Current Trends in the Management of Gastroesophageal Reflux Disease.
P2860
Q27025882-182F513E-4A7C-4232-9CD7-47DCBDE87F66Q30249468-CF2D811A-48F5-4CA4-840B-85AF2074C46CQ30436969-33178D1B-F641-45B2-BE2C-E7C6A637E828Q33212653-D0217DF0-8155-4EC8-AAC0-A17E6F1A6168Q34576807-1A8777C9-5889-4757-97E9-CBF92C2CF00BQ34895516-C9AE453C-6EFD-4BE3-B8BD-5361CDF11398Q35011174-0886C5FB-FADC-4005-83E2-47EA2E238BEDQ35049112-C9796568-24E7-4CF1-9F97-BF75B0CD7D9EQ35772657-9D19D235-64E5-4A8B-9E64-8675DAF2F688Q35885918-886C0B56-B08D-494A-A101-8FD5B9309CC2Q36191254-81CD2E98-DB2F-45AC-B5B3-55907E67C2E4Q36206560-C0765FEF-DB83-44B4-A243-E030B3F9141BQ36346427-B35F5863-C63D-4389-A554-D76ED42383B5Q36349598-AC074505-DEFA-408A-A301-F9C6A2BCF833Q36398674-F69442E3-B449-4BD4-B0BF-D1CC13BA1BE6Q36443725-F5CF8615-5030-4886-A4FE-ED032E555BDEQ36510017-7A37BB98-B1E6-4742-A7B9-4D63A279813DQ36554323-BCD33BC9-E941-4612-82E1-138F3CE4A6FCQ36752080-58908977-6B3E-4F1A-9C7F-ED253DD2693FQ36765136-1C074AD2-8853-4525-9DD7-F61324C436FAQ37134557-A0A7C8EE-734D-4745-8F32-9EC8099EC1BBQ37230841-1E8303A3-A6CA-4E85-985B-253D29F4E865Q37284534-E24E48EF-5EBB-4FFA-89B7-67257AE3F85BQ37345839-2D461598-6E8F-444C-8BD0-8CFA11779681Q37466737-50977B14-4511-42EB-814F-1AD503507A61Q37570546-D0382EB4-DE76-49D1-8C1D-BA41D24A4725Q37827182-9018DDEF-F696-4407-AE41-4E5574298B40Q37939281-43B7A1B1-4F9D-4264-AF34-86E1ACE4B7FDQ37959240-7A7B0C32-839A-493C-B453-37DDEAEA6C05Q38001073-A4377522-0E30-4420-A9FC-21096FBF5EF6Q38029727-87392ED3-0CC2-49D5-B3D3-F44F7FE9551FQ38057369-490EDDD5-11C0-428E-A976-FE06805BC9B8Q38074868-8D3E5ECC-069C-443F-B75D-3A06C78BD56EQ38123482-230B5F2E-C22C-4739-893A-C59AA9CF7C97Q38151813-16B3648F-573E-46C3-BC3E-C652910A8F3AQ38217671-6EECBF08-2488-44E5-B6BB-C38A0B9E3958Q38267393-79E0D76C-08CC-42EF-ABC0-1F9C0ED0C79AQ38599609-489CA0FD-704C-4251-B5AF-528BC1F721D2Q38609120-F3692B3B-5B23-4483-B658-86A4ED901D20Q38692672-44C71E17-3BA1-41CB-AC5D-74DC5047F6A6
P2860
Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Effect of the GABA(B) agonist ...... tory to proton pump inhibitors
@ast
Effect of the GABA(B) agonist ...... tory to proton pump inhibitors
@en
type
label
Effect of the GABA(B) agonist ...... tory to proton pump inhibitors
@ast
Effect of the GABA(B) agonist ...... tory to proton pump inhibitors
@en
prefLabel
Effect of the GABA(B) agonist ...... tory to proton pump inhibitors
@ast
Effect of the GABA(B) agonist ...... tory to proton pump inhibitors
@en
P2093
P2860
P356
P1433
P1476
Effect of the GABA(B) agonist ...... tory to proton pump inhibitors
@en
P2093
P2860
P304
P356
10.1136/GUT.52.10.1397
P407
P577
2003-10-01T00:00:00Z